Results 241 to 250 of about 26,004 (264)
Some of the next articles are maybe not open access.
Bulletin du cancer, 2015
Paclitaxel is conventionally used in a wide range of oncology indications. Nab-paclitaxel is synthesized by a process of high pressure homogenization of paclitaxel in the presence of human albumin and it was originally developed to reduce the toxicity usually associated with cremophor in soluble paclitaxel and to increase its penetration in tumor ...
Daniel, Lopez-Trabada Ataz +2 more
openaire +1 more source
Paclitaxel is conventionally used in a wide range of oncology indications. Nab-paclitaxel is synthesized by a process of high pressure homogenization of paclitaxel in the presence of human albumin and it was originally developed to reduce the toxicity usually associated with cremophor in soluble paclitaxel and to increase its penetration in tumor ...
Daniel, Lopez-Trabada Ataz +2 more
openaire +1 more source
Metabolism of the taxanes including nab-paclitaxel
Expert Opinion on Drug Metabolism & Toxicology, 2014The classical taxanes (paclitaxel, docetaxel), the newer taxane cabazitaxel and the nanoparticle-bound nab-paclitaxel are among the most widely used anticancer drugs. Despite years of research, the optimal dosing regimen (weekly vs 3-weekly) and optimal dose is still controversial, as is the value of pharmacological personalization of taxane dosing ...
openaire +2 more sources
Gemcitabine/nab‐paclitaxel for pediatric relapsed/refractory sarcomas
Pediatric Blood & Cancer, 2018AbstractBackgroundPediatric patients with relapsed/refractory sarcomas have poor outcomes and need novel therapies that provide disease control while maintaining an acceptable quality of life. The activity and toxicity of gemcitabine and nab‐paclitaxel in combination has not been reported in pediatrics.ProcedureWe reviewed the records of fifteen ...
Jonathan L. Metts +7 more
openaire +2 more sources
nab-Paclitaxel mechanisms of action and delivery
Journal of Controlled Release, 2013Taxanes are a key chemotherapy component for several malignancies, including metastatic breast cancer (MBC), ovarian cancer, and advanced non-small cell lung cancer (NSCLC). Despite the clinical benefit achieved with solvent-based (sb) taxanes, these agents can be associated with significant and severe toxicities.
openaire +2 more sources
Efficacy of nab-paclitaxel in treating metastatic melanoma
Expert Opinion on Pharmacotherapy, 2019Systemic treatment of metastatic melanoma has been revolutionized by the advent of checkpoint inhibitors and targeted agents which are widely accepted as standard front-line therapies. However, despite these major advances, a substantial portion of patients still fail checkpoint inhibitors and/or targeted agents and are not candidates for clinical ...
openaire +3 more sources
Gemcitabine and nab-paclitaxel induced interstitial pneumonia
Diagnostic and Interventional Imaging, 2021Claire Sabat +2 more
openaire +2 more sources